Brief: Egetis Says FDA's Rare Pediatric Disease Priority Review Program Extended Until 2029
04/02/2026 14:28
Feb 4 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST: FDA'S RARE PEDIATRIC DISEASE PRIORITY REVIEW PROGRAM EXTENDED UNTIL 2029 IS ELIGIBLE TO RECEIVE PRIORITY REVIEW VOUCHER (PRV), UPON APPROVAL Source text: ID:nMFN9JDQMq Further company coverage: EGTX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))